What are Natera, Inc.'s total assets?

Natera, Inc. (NTRA) holds $2.6B in total assets, up 50.9% year over year.

How much debt does Natera, Inc. have?

Natera, Inc. carries $240.1M in total debt against $1.8B of shareholders' equity, a debt-to-equity ratio of 0.14.

How much cash does Natera, Inc. have?

Natera, Inc. holds $1.1B in cash and equivalents.

Can Natera, Inc. cover its short-term obligations?

Its current ratio is 2.96 — current assets exceed current liabilities.

Where does Natera, Inc.'s balance sheet data come from?

Every line is extracted from Natera, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Natera, Inc. NTRA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$1.09B+1.1%	$1.08B+3.3%	$1.04B+4.1%	$1B+2.7%	$973.77M+3.0%
Accounts receivable, net	$417.6M+40.8%	$296.53M+3.5%	$286.38M-7.4%	$309.22M-2.8%	$318.23M+1.3%
Inventories	$70.72M+3.3%	$68.44M+5.9%	$64.64M+19.1%	$54.27M+7.8%	$50.37M+12.6%
Prepaid expenses and other current assets	$75.57M+35.4%	$55.83M+3.7%	$53.86M+3.4%	$52.1M-7.3%	$56.19M+15.5%
Derivative assets	$19.99M+57.9%	$12.66M—	——	——	——
Total current assets	$1.65B+10.3%	$1.5B+3.4%	$1.45B+1.1%	$1.43B+1.1%	$1.42B+2.9%
Property and equipment, net	$269.38M+11.7%	$241.18M+16.8%	$206.5M+9.1%	$189.22M+4.9%	$180.45M+11.4%
Accumulated depreciation	$120.41M+8.4%	$111.08M—	——	——	——
Operating lease right-of-use assets	6.5%-10,854,099,994%	10,854,100,000%+1,155,300,000%	9,698,800,000%+186,000,000%	9,512,800,000%+49,700,000%	9,463,100,000%+848,200,000%
Goodwill	$140.86M-0.2%	$141.07M—	——	——	——
Intangible assets, net	$367.36M-1.7%	$373.71M—	——	——	——
Deferred tax assets	$701K0.0%	$701K—	——	——	——
Other non-current assets	$51M+38.2%	$36.9M-47.8%	$70.68M+71.9%	$41.12M+0.5%	$40.9M+58.6%
Allowance for credit losses	$0—	$0—	——	——	——
Total assets	$2.61B+9.0%	$2.4B+31.7%	$1.82B+3.7%	$1.76B+1.4%	$1.73B+4.3%
Accounts payable	$62.4M+88.2%	$33.16M-28.7%	$46.5M+26.1%	$36.88M-6.0%	$39.24M+12.4%
Accrued expenses	$143.81M+55.3%	$92.6M+19.6%	$77.44M+40.7%	$55.03M+16.9%	$47.09M-24.2%
Deferred revenue	$36.85M+48.0%	$24.91M+14.3%	$21.79M+1.0%	$21.56M+4.9%	$20.56M+4.1%
Current portion of long-term debt	$80.31M0.0%	$80.32M0.0%	$80.34M0.0%	$80.34M0.0%	$80.35M0.0%
Operating lease liabilities, current	$14.82M-4.9%	$15.58M+11.2%	$14.01M+7.3%	$13.06M+7.0%	$12.2M+20.0%
Short-term borrowings	$80.31M0.0%	$80.32M0.0%	$80.34M0.0%	$80.34M0.0%	$80.35M0.0%
Contract liabilities	$17M-0.4%	$17.06M—	——	——	——
Total current liabilities	$558.26M+26.5%	$441.23M-0.2%	$442.02M+14.9%	$384.84M+5.2%	$365.68M+6.3%
Operating lease liabilities, non-current	$144.95M+22.4%	$118.47M+13.5%	$104.38M+1.6%	$102.74M-0.3%	$103.06M+6.7%
Operating Lease Liabilities (Total)	$159.78M+19.2%	$134.05M+13.2%	$118.39M+2.2%	$115.8M+0.5%	$115.26M+8.0%
Other non-current liabilities	$16.27M+39.2%	$11.69M—	——	——	——
Total liabilities	$125.55M+6.1%	$118.36M-79.2%	$569.29M+11.4%	$510.88M+3.7%	$492.69M+5.9%
Common stock	750M0.0%	750M+5,357,043%	14K0.0%	14K0.0%	14K+16.7%
Additional paid-in capital	$4.64B+3.3%	$4.49B+10.1%	$4.08B+2.3%	$3.98B+2.8%	$3.87B+3.0%
Retained earnings	-$2.86B-3.1%	-$2.78B+1.7%	-$2.82B-3.2%	-$2.74B-3.8%	-$2.63B-2.6%
Accumulated other comprehensive income (loss)	-$202K+21.7%	-$258K-38.0%	-$187K+34.8%	-$287K-45.7%	-$197K+42.7%
Total stockholders' equity	$1.77B+3.6%	$1.71B+36.8%	$1.25B+0.5%	$1.25B+0.5%	$1.24B+3.7%
Total liabilities and stockholders' equity	$2.61B+9.0%	$2.4B+31.7%	$1.82B+3.7%	$1.76B+1.4%	$1.73B+4.3%
Available-for-Sale Debt Securities - Amortized Cost	$1.09B+1.1%	$1.08B—	——	——	——
Allowance for Credit Losses - Receivable (Current)	$7.93M-1.1%	$8.02M—	——	——	$7.43M+2.4%
Allowance for Doubtful Accounts	$7.93M-1.1%	$8.02M—	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	$7.93M-1.1%	$8.02M—	——	——	——
Cash, Cash Equivalents, and Marketable Securities	$1.09B+1.1%	$1.08B—	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$51M+38.2%	$36.9M-47.8%	$70.68M+71.9%	$41.12M+0.5%	$40.9M+58.6%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	$28.34M—	——	——	——	——
Finite Lived Intangible Assets - Gross	$379.37M+0.2%	$378.6M—	——	——	——
Investments - Amortized Cost Basis	$1.09B+1.1%	$1.08B—	——	——	——
Net Investment in Lease	$133.99M+23.4%	$108.54M+11.9%	$96.99M+2.0%	$95.13M+0.5%	$94.63M+9.8%
Intangible assets — net	$367.36M-1.7%	$373.71M—	——	——	——
Other intangible assets—net	$367.36M-1.7%	$373.71M—	——	——	——
Operating lease right-of-use assets	$133.99M+23.4%	$108.54M+11.9%	$96.99M+2.0%	$95.13M+0.5%	$94.63M+9.8%
Other non-current assets	$51M+38.2%	$36.9M-47.8%	$70.68M+71.9%	$41.12M+0.5%	$40.9M+58.6%
Property, plant and equipment at cost	$389.79M+10.7%	$352.26M—	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$133.99M+23.4%	$108.54M+11.9%	$96.99M+2.0%	$95.13M+0.5%	$94.63M+9.8%
Software and Technology Licenses, Net	$51M+38.2%	$36.9M-47.8%	$70.68M+71.9%	$41.12M+0.5%	$40.9M+58.6%
Accrued Litigation	$33M+1.2%	$32.6M—	——	——	——
Accrued Manufacturing Costs	$143.81M+55.3%	$92.6M+19.6%	$77.44M+40.7%	$55.03M+16.9%	$47.09M-24.2%
Accrued Marketing and Advertising Expenses	$27.62M+36.6%	$20.22M—	——	——	——
Accrued Progress Collections and Price Adjustments	$17M-0.4%	$17.06M—	——	——	——
Compensation and benefits	$143.81M+55.3%	$92.6M+19.6%	$77.44M+40.7%	$55.03M+16.9%	$47.09M-24.2%
Other accrued liabilities	$212.54M+12.7%	$188.66M-12.6%	$215.95M+13.0%	$191.03M+7.1%	$178.45M+21.5%
Lease Liability Payments - 2020 (Remaining Three Months)	$18.62M—	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	$27.46M—	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$28.03M—	——	——	——	——
Lease Liability Payments - Due Year Two	$27.46M—	——	——	——	——
Lease Liability Payments - Due Year Three	$27.63M—	——	——	——	——
Lease Liability Payments - Due Year Four	$28.03M—	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	$24.57M—	——	——	——	——
Operating Lease Liability Payments Due	$204.49M—	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	$44.72M—	——	——	——	——
Professional Service Fees Payable	$58.98M+5.2%	$56.08M—	——	——	——
Contingent Consideration Liability (Non-Current)	$103.2M+6.6%	$96.78M—	——	——	——
Contract Liabilities, Non-Current	$17M-0.4%	$17.06M—	——	——	——
Operating Lease Liability Payments - 2026 (Lessee)	$27.63M—	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	$27.63M—	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	$28.03M—	——	——	——	——
Long-term debt collateral	$150M—	——	——	——	——
Marketing and selling	$27.62M+36.6%	$20.22M—	——	——	——
Deferred revenue, net of current portion	$17M-0.4%	$17.06M—	——	——	——
Unrecognized Tax Benefits - Income Tax Penalties and Interest Accrued	$0—	$0—	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.00—	——	——	——
Common Stock Shares Issued	142.7M+2.2%	139.7M—	——	——	——
Additional paid-in capital	$4.64B+3.3%	$4.49B+10.1%	$4.08B+2.3%	$3.98B+2.8%	$3.87B+3.0%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$14K0.0%	$14K0.0%	$14K0.0%	$14K0.0%	$14K+16.7%
Share-Based Payment Award Options Outstanding - Number	3.2M-9.7%	3.6M—	——	——	——
Unrealized Gains on Investments	$0—	$0—	——	——	——
Unrealized Losses on Investments (Before Tax)	$0—	$0—	——	——	——
Weighted Average Exercise Price of Outstanding Options	$28.77+6.4%	$27.03—	——	——	——
Cumulative Cost Basis	$1.09B+1.1%	$1.08B—	——	——	——
Line of Credit Remaining Borrowing Capacity	$20M—	——	——	——	——
Accrued charges for third-party testing	$3.45M-83.5%	$20.87M—	——	——	——
Clinical trials and studies	$19.61M+35.5%	$14.47M—	——	——	——
Property and equipment purchases	$22.39M+98.7%	$11.27M—	——	——	——
Accrued Insurance Current And Noncurrent	$9.65M+1.5%	$9.51M—	——	——	——
Accrued Professional Fees Current And Noncurrent	$58.98M+5.2%	$56.08M—	——	——	——
Accrued shipping charges	$2.04M-40.2%	$3.42M—	——	——	——
Accrued third-party service fees	$20.48M+110%	$9.76M—	——	——	——
Testing and laboratory materials from suppliers	$21.09M+70.7%	$12.35M—	——	——	——
Allowance for doubtful accounts	$7.93M-1.1%	$8.02M—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0—	$0—	——	——	——
Gross Unrealized Gains	$0—	$0—	——	——	——
Total	$1.09B+1.1%	$1.08B—	——	——	——
Available for sale investments	$1.09B+1.1%	$1.08B—	——	——	——
Business Combination, Contingent Consideration, Liability	$125.55M+6.1%	$118.36M—	——	——	——
Clinical samples payable	$3.7M—	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$0—	——	——	——
Common stock, shares authorized (in shares)	$750M0.0%	$750M—	——	——	——
Common stock, shares issued (in shares)	$142.73M+2.2%	$139.69M—	——	——	——
Common Stock, Shares, Outstanding	$142.73M+2.2%	$139.69M—	——	——	——
Contract with Customer, Liability	$53.86M+28.3%	$41.97M—	——	——	$37.26M+1.8%
Debt instrument, collateral amount	$150M—	——	——	——	——
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0—	$0—	——	——	——
Deferred Tax and Other Liabilities, Noncurrent	$701K0.0%	$701K—	——	——	——
2031 and thereafter	$231.96M—	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$12.01M+146%	$4.88M—	——	——	——
2028	$28.61M—	——	——	——	——
2030	$28.34M—	——	——	——	——
Remainder of 2026	$21.48M—	——	——	——	——
2027	$28.64M—	——	——	——	——
2029	$28.34M—	——	——	——	——
Gross Carrying Amount	$379.37M+0.2%	$378.6M—	——	——	——
Goodwill, Gross	——	$141.1M—	——	——	——
Lessee Operating Lease Liability Payments Due	$204.49M—	——	——	——	——
2031 and thereafter	$78.18M—	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	$44.72M—	——	——	——	——
Estimated litigation liability	$33M+1.2%	$32.6M—	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.07—	——	——	——	——
Other accrued expenses	$3.03M-55.3%	$6.77M—	——	——	——
Purchase Obligation	$261.4M—	——	——	——	——
Sales and income tax payable	$9.39M+12.3%	$8.37M—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$3.24M-9.7%	$3.59M—	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$28.77+6.4%	$27.03—	——	——	——
Penalties and interest accrued on unrecognized tax benefits	$0—	$0—	——	——	——
Purchase Obligation	$261.4M—	——	——	——	——
Remainder of Fiscal Year 2024	$18.62M—	——	——	——	——
Remainder of Fiscal Year 2025	$21.48M—	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Natera, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Natera, Inc.'s total assets?: Natera, Inc. (NTRA) holds $2.6B in total assets, up 50.9% year over year.
How much debt does Natera, Inc. have?: Natera, Inc. carries $240.1M in total debt against $1.8B of shareholders' equity, a debt-to-equity ratio of 0.14.
How much cash does Natera, Inc. have?: Natera, Inc. holds $1.1B in cash and equivalents.
Can Natera, Inc. cover its short-term obligations?: Its current ratio is 2.96 — current assets exceed current liabilities.
Where does Natera, Inc.'s balance sheet data come from?: Every line is extracted from Natera, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.